CER was 20 360,90 USD for one patient with viral load <50 copies/ml (16 462,65–41 640,81 USD in sensitivity analysis). Cost of one patient with achieved viral load <50 copies/ml was lower for ETR group. CONCLUSIONS: According to the model ETR seems to be much more effective than placebo with affordable CER incremental ratio. Evaluation of ETR treatment costeffectiveness in common practice in Ru...

Materials and methods This study was conducted at a national level, using the government, patients and family’s perspectives. Both primary and secondary data were used. A cross-sectional survey was conducted in the year 2008. Data were also obtained from both national and international literature and databases. The concepts of Disability Adjusted Life Year, Cost of Illness estimation and Genera...

This appendix presents information on sources of data and methods of calculation used in OTA’s costeffectiveness analysis of strategies for newborn screening, which is presented in chapter 5. That chapter considered seven different strategies offering different combinations of tests for phenylketonuria (PKU), congenital hypothyroidism, galactosemia, maple syrup urine disease (MSUD), and homocys...

Decision makers are frequently faced with the question of how realistic are cost-effectiveness models. Overall survival (OS) is a desired clinical trial and health technology assessment endpoint but frequently unrealistic or elusive at the point of new drugs financing decision. We aim to compare the overall survival from lenalidomide treatment in relapsed/refractory multiple myeloma (rrMM) pati...

We appreciate the efforts of the California Air Resources Board (CARB) to develop economic frameworks and tools for the package of policies necessary to implement California Global Warming Solutions Act of 2006 (AB 32) and meet the requirements of the law. These comments are submitted in response to the April 25, 2008 Economic Analysis Technical Stakeholder Working Group meeting – which focused...

Objectives This three-year, international, multicentre, longitudinal, observational, cost-effectiveness study named RaDiCEA (RareDisease &Cost-EffectivenessAnalysis) will assess the economic evaluation (cost of illness COI and costeffectiveness analysis CEA) of innovative therapies (i.e., anti IL-1 agents), quality of life (QoL) and effects of the prevention of otherwise irreversible central ne...

Methods: Ammonia concentrations in farrowing, nursery, finisher, and gestating barns were monitored for 8 weeks using both the pHydrionTM test strips and the DraegerTM unit. The ammonia measurements were compared using bivariate correlation analysis. Average ammonia concentrations in each barn type were compared using an ANOVA. The precision and costeffectiveness of each assay were demonstrated...

Introduction: This paper demonstrates that standard cost-effectiveness screening of pharmaceutical drugs may give misleading results if systematic data heterogeneity by base health related quality of life (BHRQoL), the HRQoL immediately prior to treatment, is ignored. Study Design: It is argued that for some chronic diseases, such as rheumatoid arthritis, the magnitude of the HRQoL response to ...